Trial Profile
A Phase II Study of Subcutaneous Bevacizumab in Relapsed/Progressive Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 14 Apr 2018 Status changed from active, no longer recruiting to completed.
- 17 May 2017 Planned End Date changed from 1 Jun 2018 to 1 May 2018.
- 17 May 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.